These are KEI’s post hearing responses to three questions regarding USTR’s Special 301 list.
One question was a follow up to KEI’s testimony that USTR should develop a policy on the trade related aspects of biomedical R&D that does not rely solely on higher drug prices, particularly given the dramatic changes in the proportion of the US and world population that is 65 or older.
The second question asked which trading partners are undermining the mandatory exceptions in the Berne Convention on Copyright for news of the day and quotations.
The third question asked if countries that allowed copyright holders to opt-out of AI training data should be placed on the Special 301 list.